# Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

> **NCT03723681** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Quizartinib

## Key facts

- **NCT ID:** NCT03723681
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-05
- **Primary completion:** 2022-03-03
- **Final completion:** 2022-03-03
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03723681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03723681, "Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03723681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*